Village Farms (VFF) Q2 2026 earnings review
International Exports Ignite Margins, But Dilution Raises Eyebrows
Village Farms delivered a robust Q2, highlighted by its fifth consecutive quarter of positive net income. Total revenue grew 7% YoY to $64M, but the real story is operating leverage: Cannabis gross margin exploded to 51% (up from 42% a year ago), driving a 16% increase in Adjusted EBITDA from continuing operations. The growth engine is undeniably the international medical export business, which surged 74% YoY to a record $20.9M. However, management's decision to execute a $15M registered direct equity offering—despite sitting on $73M in cash and having recently completed share buybacks—starkly contradicts their prior 'disciplined capital allocation' narrative.
🐂 Bull Case
Cannabis gross margins hit 51%, significantly above the company's historical 30-40% target. This was driven by record yields, improved production costs, and a mix shift toward highly profitable international exports.
The company's six-year investment in EU-GMP certification is yielding massive dividends. International sales reached a record $20.9M, proving VFF can maintain pricing power in Europe while competitors face margin compression.
🐻 Bear Case
Raising $15M via equity at the expense of shareholder dilution is baffling when the company holds $73M in cash, generates positive operating cash flow, and just spent millions on buybacks in prior quarters.
While international flies high, the North American business is dragging. Canadian Branded sales fell 8% YoY, Canadian Non-Branded plunged 57% YoY, and the U.S. Cannabis segment dropped 16% YoY.
⚖️ Verdict: ⚪
Neutral to Bullish. Operationally, the cannabis business is executing flawlessly with exceptional margin expansion and international growth. However, capital allocation decisions (dilutive equity raise) introduce a layer of governance risk that warrants caution.
Key Themes
International Exports Dominating Growth
Accelerating. International export sales surged 74% YoY and 43% sequentially to a record $20.9M. The company's massive EU-GMP certified facility in Delta, BC provides a structural competitive advantage, allowing VFF to capture significant market share in Germany as local regulations tighten on non-compliant competitors.
Record Yields Driving Margin Expansion
Accelerating. Cannabis gross margin expanded 900 basis points YoY to 51%. Management attributes this to record harvest yields in the Delta facilities during H1 2026, leading to improved unit costs of production. Favorable sales mix (more international volume) compounded the margin strength.
Delta 2 Tech Upgrades Accelerated
Stable. The company harvested its first crop from the Delta 2 greenhouse expansion and announced it is accelerating technology upgrades ahead of schedule due to robust global demand. This facility is expected to add 15 metric tonnes of capacity in H2 2026 and reach a 40-tonne run rate by mid-2027.
Capital Allocation Contradictions
Management previously touted a 'highly disciplined' approach, evidenced by a completed $10M share buyback program. Yet in Q2, they issued 7.5M shares to institutional investors for $15M. Diluting shareholders while sitting on $73M in cash and generating positive cash flow directly contradicts their stated capital discipline narrative.
U.S. Cannabis Segment Continues to Bleed
Decelerating. The U.S. Cannabis segment (CBD/hemp) remains a persistent drag, with revenues falling 16% YoY to $3.2M. The company remains in a holding pattern, waiting on U.S. federal rescheduling and regulatory clarity before committing meaningful capital, but current operations continue to shrink.
Macro: European Regulatory Standards Tightening
A key macro theme working in VFF's favor is the stricter enforcement of quality standards in European medical markets, particularly Germany. Competitors relying on GACP or 'greenwashed' product are being squeezed, validating VFF's long-term investment in strict EU-GMP certification.
Other KPIs
Reversing. OCF swung back to a positive $8.9M in Q2, recovering from a steep negative $16.8M in Q1 2026 (which was heavily impacted by a one-time $12.1M Canadian corporate tax payment). This proves the core business is highly cash generative.
Decelerating aggressively. Dropped 57% YoY from $7.1M in 25Q2. While the company is successfully pivoting capacity to high-margin international exports, this steep drop reflects either an intentional strategic exit from low-margin wholesale or severe domestic B2B pricing pressure.
Guidance
Accelerating. The new capacity is actively coming online. Generating an additional 15 tonnes in the second half of the year provides a clear line of sight to continued revenue growth, specifically earmarked for high-demand international channels.
Accelerating. The Groningen facility will push maximum annualized production capacity in the Netherlands to approximately 10 metric tonnes. This represents a massive increase from current levels and positions the company to dominate the regulated Dutch experiment.
Key Questions
Rationale for Equity Raise
With $73M in cash on the balance sheet and positive operating cash flow, why did the company feel it was necessary to issue 7.5M shares and dilute equity holders for a mere $15M?
Sustainability of 51% Gross Margins
Cannabis gross margins breached 50%, far above the historical 30-40% target. How much of this was driven by one-time harvest yield records versus structural pricing power in Germany?
Domestic B2B Collapse
Canadian Non-Branded sales fell 57% YoY. Is the company intentionally exiting this channel to redirect biomass to international markets, or is the Canadian wholesale market collapsing?